The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Allergan's revenues will expand 7.5% and EPS will increase 19.0%.
The average estimate for revenue is $1.51 billion. On the bottom line, the average EPS estimate is $1.19.
Last quarter, Allergan booked revenue of $1.41 billion. GAAP reported sales were 6.4% higher than the prior-year quarter's $1.33 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.06. GAAP EPS of $0.82 for Q3 were 1.2% higher than the prior-year quarter's $0.81 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 86.6%, 80 basis points better than the prior-year quarter. Operating margin was 25.4%, 100 basis points worse than the prior-year quarter. Net margin was 17.6%, 120 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $5.80 billion. The average EPS estimate is $4.18.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 414 members out of 436 rating the stock outperform, and 22 members rating it underperform. Among 130 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 127 give Allergan a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allergan is outperform, with an average price target of $100.98.
- Add Allergan to My Watchlist.